Abstract 427P
Background
Several important factors affect directly or indirectly the quality of life of women with cancer in India. Several unmet needs were found to be unaddressed. This program aims to empower the patient, improve quality of life and encourage them to actively participate in the healing process. Hospitals and oncologists are challenged to develop programs that support the growing number of cancer patients. Failure to address leads to decreased compliance and outcomes.
Methods
Patients will be enrolled to participate in the introductory half a day program after obtaining informed consent and completing the pre assessment form (physical, psychological and socio-economic domains, along with demography, diagnosis and details of treatment received). Program deals with confidence building tips on grooming, Skin and hair care, management of external prosthesis and wigs, lymphedema prevention, Nutritional advice, De-stressing and relaxation techniques Functional exercises for fitness and rehabilitation through supervised fitness and restorative yoga practices. Following the introductory program women are invited to join the 5 day session. The main intervention during this period is supervised yoga, motivation and counseling, meditative practices, guided relaxation, music, dance therapy. The tools used for assessment pre and post intervention are the assessment questionnaire and Hospital Anxiety and Depression (HADS) scale. Many of the physical problems in these women led to emotional problems such as anxiety and depression hence the HADS scale was used.
Results
370 patients were enrolled in the study-86% of patients had breast cancer. Age ranged between 26-76 years. 75% of patients were below 60 years. 18% of the patients below 40 years had breast cancer. The burden of unmet needs was primarily issues related to appearance, hair loss, skin changes, body image, arm swelling, impairment of cognitive factors and emotional problems like depression, anxiety and worry. The percentage of patients with anxiety and depression pre and post interventionTable:
427P
HADS DEPRESSION SCORE | PRE-INTERVENTION | POST-INTERVENTION |
---|---|---|
BORDER LINE (8-10) | 12.50% | 0% |
ABNORMAL (11-21) | 12.50% | 0% |
HADS ANXIETY SCORE | PRE-INTERVENTION | POST-INTERVENTION |
BORDER LINE (8-10) | 18.80% | 0% |
ABNORMAL (11-21) | 37.50% | 0% |
Conclusions
This preliminary study shows that such unique, multidimensional supportive care programs have a significant impact on quality of life through treatment into survivorship phase.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P.P. Bapsy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract